Jonderko G, Marcisz C
Z Gesamte Inn Med. 1979 Aug 1;34(15):408-11.
The examinations were performed on 3 groups of altogether 65 persons with thyreotoxicosis, the cause of which was either Basedow's disease or struma nodosa. The first group received metizol (thiamazol) in a daily dosage of 60 mg, the second group lithium carbonate (1.0 up to 1.5 g/a day), the third group metizol together with lithium carbonate. The groups were of the same value, concerning the degree of the symptoms of hyperthyroidism. The examinations showed that when lithium carbonate is used alone at the earliest a significant decrease of the serum T4 and T3 concentration as well as of the T3 binding index appears. After a treatment of seven days the therapeutic effects even up. Under the lithium therapy an essential improvement of the clinical findings was achieved. The combined therapy with lithium and metizol did not exhibit any advantages in this respect. The side-effects observed under the lithium therapy are no essential clinical problem.
对总共65例甲状腺毒症患者进行了检查，这些患者的病因要么是突眼性甲状腺肿，要么是结节性甲状腺肿。第一组患者每日服用60毫克甲巯咪唑（他巴唑），第二组患者每日服用1.0至1.5克碳酸锂，第三组患者同时服用甲巯咪唑和碳酸锂。就甲状腺功能亢进症状的严重程度而言，这几组患者情况相当。检查结果显示，单独使用碳酸锂时，最早在用药后血清T4和T3浓度以及T3结合指数就会出现显著下降。经过七天的治疗，治疗效果趋于平稳。在锂盐治疗下，临床症状有了实质性改善。在这方面，锂盐与甲巯咪唑联合治疗未显示出任何优势。锂盐治疗中观察到的副作用并非严重的临床问题。
